DOTBIO
DotBio develops multi-functional antibodies based on its proprietary DotBody technology as the next generation of cancer therapies. DotBio develops antibody therapies that target, at multiple junctions, the interplay between tumors and the tumor microenvironment to re-establish an effective immune response. Our proprietary technologies enable the ยญrapid generation of multi-specific antibodies targeting multiple processes. The rapid testing of combinatorial ensembles of multi-specific antibody prototypes can directly identify molecules re-activating the tumor immune response with novel synergistic mechanisms.
DOTBIO
Social Links:
Industry:
Biotechnology Life Science Medical
Founded:
2017-01-01
Address:
Singapore, Central Region, Singapore
Country:
Singapore
Website Url:
http://www.dotbiopharma.com
Total Employee:
1+
Status:
Active
Contact:
+65 6906 0743
Email Addresses:
[email protected]
Total Funding:
2.48 M USD
Technology used in webpage:
SPF Google Apps For Business Squarespace Hosted Google DNS Google Domains Google Cloud DNS
Current Employees Featured
Founder
Investors List
Enterprise Singapore
Enterprise Singapore investment in Grant - DotBio
Official Site Inspections
http://www.dotbiopharma.com
- Host name: 198.49.23.145
- IP address: 198.49.23.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "DotBio"
DotBio - Crunchbase Company Profile & Funding
Organization. DotBio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone โฆSee details»
Team โ DotBio
Ignacio Asial, PhD MSc MEng Founder and CEO . Kelly Hew, PhD Chief Operating Officer . BOARD OF DIRECTORSSee details»
DotBio Information - RocketReach
The company was founded by Professor Pär Nordlund and Dr. Ignacio Asial, who designed and conceptualized the DotBody technology based on their expertise in protein and antibody โฆSee details»
DotBio Company Profile | Management and Employees List
DotBio Profile and History. DotBio is a highly innovative biopharmaceutical company with a mission to harness next-generation antibody technologies to bring more effective therapies to โฆSee details»
DotBio - LinkedIn
DotBio is proud to announce our collaboration with Bora Biologics, Taiwan's largest contract development and manufacturing organization (CDMO), for the clinical development of our innovative tri ...See details»
Contact Us โ DotBio
DotBio is always looking for talented and motivated individuals with experience in the development of antibody-based therapies. For more information on career opportunities at โฆSee details»
DotBio - 2025 Company Profile - Tracxn
Mar 23, 2025 DotBio is a seed company based in Singapore (Singapore), founded in 2018 by Ignacio Asial and Par Nordlund. It operates as a Provider of antibody-based therapies.DotBio โฆSee details»
Dotbio Pte Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Www.dotbiopharma.com. Last update 08 Mar 2025. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. Tags. Neoplasms. ...See details»
Nextsource | Company Profile | DotBio
Explore the company profile of DotBio (dotbiopharma.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»
DotBio Company and Investment Profile | MAGNiTT
DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic โฆSee details»
Dotbio - Overview, News & Similar companies | ZoomInfo.com
View Dotbio (www.dotbiopharma.com) location in Singapore , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
DotBio successfully launches to focus on next generation of
Singapore, 6 August 2018 โ DotBio, a new company focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, has officially launched and โฆSee details»
DotBio launches focusing on immuno-oncology drugs
Aug 6, 2018 DotBio, a new company focused on the development of novel immuno-oncology drugs based on humanised domain antibodies, has officially launched and has successfully โฆSee details»
Technology โ DotBio
DotBio is a biopharmaceutical company specialized in next-generation antibody therapies. DOTBIO SEEKS TO PIONEER NEXT-GENERATION ANTIBODY THERAPIES We aim to โฆSee details»
DotBio Pte Ltd_ๆ่่ตๆๆฐๆ ๅต_ๆฉ็ตๅป่ฏ (ๅ่ฏ่ไบ)
DotBio, founded in June 2017 in Singapore as a spin-off from the Karolinska Institute and Nanyang Technological University, is focused on immuno-oncology drugs based on domain โฆSee details»
Pipeline โ DotBio
DotBio is developing an internal pipeline of innovative, multi-functional antibody therapies to treat and cure cancer. (Currently undisclosed)See details»
Proactive policy helps woo foreign investors - China.org.cn
2 days ago This photo taken on April 26, 2024 shows a BMW electric vehicle displayed at the signing ceremony for deepening strategic cooperation between BMW and Shenyang, in โฆSee details»
Nanogel drug delivery system shows promise for treating โฆ
Mar 12, 2025 Graphical abstract. Credit: Nanomedicine: Nanotechnology, Biology and Medicine (2025). DOI: 10.1016/j.nano.2025.102812See details»
News - DotBio
Oct 8, 2024 The Asian Fund for Cancer Research is a non-profit organization committed to funding cancer research, especially those cancers prevalent in Asian populations. It also โฆSee details»
DotBody Technology โ DotBio
The DotBody technology has been validated in the pre-clinical studies, displaying positive results. DotBioโs key differentiation is the ability to produce many antibody prototypes in parallel, โฆSee details»